| Title: |
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial [version 1; referees: 3 approved] |
| Authors: |
Ray Y. Chen, Laura E. Via, Lori E. Dodd, Gerhard Walzl, Stephanus T. Malherbe, André G. Loxton, Rodney Dawson, Robert J. Wilkinson, Friedrich Thienemann, Michele Tameris, Mark Hatherill, Andreas H. Diacon, Xin Liu, Jin Xing, Xiaowei Jin, Zhenya Ma, Shouguo Pan, Guolong Zhang, Qian Gao, Qi Jiang, Hong Zhu, Lili Liang, Hongfei Duan, Taeksun Song, David Alland, Michael Tartakovsky, Alex Rosenthal, Christopher Whalen, Michael Duvenhage, Ying Cai, Lisa C. Goldfeder, Kriti Arora, Bronwyn Smith, Jill Winter, Clifton E. Barry III, Predict TB Study Group |
| Source: |
Gates Open Research, Vol 1 (2017) |
| Publisher Information: |
F1000 Research Ltd, 2017. |
| Publication Year: |
2017 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
Antimicrobials & Drug Resistance, Bacterial Infections, Immunological Biomarkers, Medicine |
| More Details: |
Background: By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%. One trial shortened treatment only among those without baseline cavity on chest x-ray and whose month 2 sputum culture converted to negative. The 4-month arm relapse rate decreased to 7% but was still significantly worse than the 6-month arm (1.6%, P |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2572-4754 |
| Relation: |
https://gatesopenresearch.org/articles/1-9/v1; https://doaj.org/toc/2572-4754 |
| DOI: |
10.12688/gatesopenres.12750.1 |
| Access URL: |
https://doaj.org/article/2e9744f070dd42cc8f0373c77478494c |
| Accession Number: |
edsdoj.2e9744f070dd42cc8f0373c77478494c |
| Database: |
Directory of Open Access Journals |
